COEGIN — Coegin Pharma AB Share Price
Last trade - 00:00- SEK45.97m
- SEK40.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.81 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -411.97% | ||
| Return on Equity | -201.53% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.57 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Coegin Pharma AB, formerly GoldBlue AB (publ) is a Sweden-based biotechnology company. The Company focuses on the development of small molecule therapies aimed at the key enzyme, which is known for its involvement in a variety of inflammatory diseases as well as in cancer. Coegin Pharma AB provides consulting and management services in drug development as well.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 28th, 2016
- Public Since
- February 21st, 2018
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Nordic Growth Market - Stockholm
- Shares in Issue
- 15,961,467
- Address
- c/o Medicon Village, LUND, 223 81
- Web
- https://coeginpharma.com/
- Phone
- +46 855925266
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Similar to COEGIN
ATTANA AB
Nordic Growth Market - Stockholm
Lumito AB (publ)
Nordic Growth Market - Stockholm
Lumito AB (publ)
Nordic Growth Market - Stockholm
Prolight Diagnostics AB (publ)
Nordic Growth Market - Stockholm
FAQ
As of Today at 19:05 UTC, shares in Coegin Pharma AB are trading at SEK2.88. This share price information is delayed by 15 minutes.
Shares in Coegin Pharma AB last closed at SEK2.88 and the price had moved by -76.56% over the past 365 days. In terms of relative price strength the Coegin Pharma AB share price has underperformed the FTSE Global All Cap Index by -77.99% over the past year.
There is no consensus recommendation for this security.
Coegin Pharma AB does not currently pay a dividend.
Coegin Pharma AB does not currently pay a dividend.
Coegin Pharma AB does not currently pay a dividend.
To buy shares in Coegin Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK2.88, shares in Coegin Pharma AB had a market capitalisation of SEK45.97m.
Here are the trading details for Coegin Pharma AB:
- Country of listing: Sweden
- Exchange: NGM
- Ticker Symbol: COEGIN
Based on an overall assessment of its quality, value and momentum Coegin Pharma AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Coegin Pharma AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -55.9%.
As of the last closing price of SEK2.88, shares in Coegin Pharma AB were trading -44.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Coegin Pharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK2.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Coegin Pharma AB's directors